International application No. PCT/CA2005/000025

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7): C12N-15/11, C07K-7/06, C07K-16/16, A23L-1/29, C07K-14/415, C12N-15/29, G01N-33/02, G01N-33/48, G01N-33/564

According to International Patent Classification (IPC) or to both national classification and IPC

### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)
IPC(7): C12N-15/11, C07K-7/06, C07K-16/16, A23L-1/29, C07K-14/415, C12N-15/29, G01N-33/02, G01N-33/48, G01N-33/564


Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)
DELPHION, ESPACENET, WEST, BIOSIS, CAPLUS, ESBIOBASE, MEDLINE, CAS REGISTRY, GENBANK. Keywords: diabetes, epitope, gliadin, wheat (storage globulin), gbl1

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	OKITA, T.W. et al. Evolution and heterogeneity of the α-/β-type and γ-type gliadin DNA sequences. Journal of Biological Chemistry, 5 July	1, 3, 6, 8-12
A	1985, Vol. 260, No. 13, pages 8203-8213, ISSN 0021-9258 Figures 3 & 4	2, 4, 5, 7, 13-25
X	LITTS, J.C. et al. Genomic nucleotide sequence of a triticum aestivum 7S globulin (Gbl1) storage protein gene. GenBank nucleotide sequence	1, 3, 6, 8-12
A	database. Bethesda, MD: National Center for Biotechnology Information, 27 April 1993 [retrieved on 2005-04-20]. Retrieved from the Internet: <url:< td=""><td>2, 4, 5, 7, 13-25</td></url:<>	2, 4, 5, 7, 13-25
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=1706 95>, accession no. M81719.	
	- cited in the application	

	- 1				
[X]	Further of	documents are listed in the continuation of Box C.	[X]	See patent family annex.	
*	Special	categories of cited documents :	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand	
"A"	docume to be of	ent defining the general state of the art which is not considered f particular relevance	"X"	the principle or theory underlying the invention	
"E"	earlier : filing d	plication or patent but published on or after the international		document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L"	docume cited to special	ent which may throw doubts on priority claim(s) or which is establish the publication date of another citation or other reason (as specified)	"Ү"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O"	docum	ent referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	
"P"	documents the price	ent published prior to the international filing date but later than ority date claimed		,	
Date	of the a	ctual completion of the international search	Date	of mailing of the international search report	
20 April 2005 (20-04-2005)		11 M	11 May 2005 (11-05-2005)		
	Name and mailing address of the ISA/CA Canadian Intellectual Property Office		Auth	Authorized officer	
Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001(819)953-2476		Michael W. De Vouge (819) 997-2952			



Box	N	0. 1	Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)			
This reas			national search report has not been established in respect of certain claims under Article 17(2)(a) for the following			
1.	. [ ] Claim Nos.:					
	-	-	because they relate to subject matter not required to be searched by this Authority, namely:			
2.	[X	[]	Claim Nos.: 8, 12, 13, 21, 24, 25			
			because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
			Searches of claims 8, 12, 13, 21, 24 and 25 have been restricted to nucleotide sequences and kits comprising or encoding diabetogenic epitopes of gliadin isoforms or gbl1, as the claimed subject matter is only defined by functional rather than structural attributes, thereby rendering impossible a search over the entire scope of the claims.			
3.	Ţ	]	Claim Nos. :			
			because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box	No	. I	II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)			
This	Int	em	ational Searching Authority found multiple inventions in this international application, as follows:			
- inc	lica	ted	on extra sheet			
1.	[	_	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2.	[	]	As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.			
3.	[	1	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos.:			
4.	[X	[]	No required additional search fees were timely paid by the applicant. Consequently, this international search report is			
			restricted to the invention first mentioned in the claims; it is covered by claim Nos.: 1-25			
			Remark on Protest [ ] The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.			
			[ ] The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.			
			[ ] No protest accompanied the payment of additional search fees.			

ategory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OSMAN, A.A. et al. A monoclonal antibody that recognizes a potential	14, 17-20
A	coeliac-toxic repetitive pentapeptide epitope in gliadins. European Journal of Gastroenterology and Hepatology, October 2001, Vol. 13, No. 10, pages 1189-1193, ISSN 0954-691X.  - the entire document	1-13, 15, 16, 21-25
х	GIL GARCIA, J.R. et al. Development of a monoclonal antibody capable of detecting prolamine in wheat and oats. Hybridomas and Hybridomics,	14, 17-20
A	December 2003, Vol. 22, No. 6, pages 383-388, ISSN 1536-8599 the entire document	1-13, 15, 16, 21-25
X	WO01/25793 A2 (ISIS INNOVATION (GB)) 12 April 2001 - pages 20-26	1, 3-6, 8-14, 17-22, 24, 25
A	- pages 20-20	2, 7, 15, 16, 23
P, X	US2004216190 A1 (KOVALIC, DAVID K (US)) 28 October 2004	1, 3, 6, 8-12
A	- SEQ ID NOs: 4427, 9971	2, 4, 5, 7, 13-25
A	MacFARLANE, A.J. et al. A Type 1 diabetes-related protein from wheat ( <i>Triticum aestivum</i> ). Journal of Biological Chemistry, January 3, 2003, Vol. 278, No. 1, pages 54-63, ISSN 0021-9258.	1-25

Infort on patent family members

International application No. PCT/CA2005/000025

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO0125793 A2	12-04-2001	AU7539400 A	10-05-2001
		CA2386089 A1	12-04-2001
		EP1218751 A2	03-07-2002
		GB9923306D D0	08-12-1999
		JP2003511670T T	25-03-2003
		MXPA02003295 A	02-09-2002
US2004216190 A1	28-10-2004	US2004031072 A1	12-02-2004
		US2004034888 A1	19-02-2004
		US2004214272 A1	28-10-2004

International application No.

...continued from Box III

The International Search authority found multiple groups of inventions in this international application, as follows:

I. Claims 1-25:

Amino acid sequences comprising diabetogenic epitopes, nucleotide sequences encoding such epitopes, antibodies reactive with such epitopes, and kits.

II. Claims 26 and 27:

Method of screening foodstuffs to identify immunogenic proteins therewithin.

III. Claims 28-32:

Foodstuffs modified to reduce or eliminate diabetogenic epitopes.

IV. Claims 33-35:

Method of screening a subject for reactivity toward food proteins.

The special technical feature linking claims of Invention I is considered to be the identification of diabetogenic epitopes, in particular those from gliadin and gbl1. Claims of Inventions II and IV are held to be distinct from Invention I in that the claimed methods as recited are generic and do not utilize or exploit said special technical feature. Claims of Invention III are held to be distinct from those of Invention I in that the claimed products of each invention are structurally dissimilar and fail to share said special technical feature.